Praxis Precision Medicines, Inc.
0 products tracked · names used in filings: Praxis Precision Medicines, Inc.
Upcoming milestones
ulixacaltamide: PDUFA target action date (essential tremor)
Praxis Precision Medicines, Inc. (PRAX); ulixacaltamide HCl; NDA; status: set; "Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results FDA reviews of relutrigine, with PDUFA target action date of December 27, 2026, and ulixacaltamide HCI, with PDUFA target action date of January 29, 2027, are ongoing Topline results from the EMERALD study of…"; filed 2026-11-09 · source
relutrigine: PDUFA target action date (SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs))
Praxis Precision Medicines, Inc. (PRAX); NDA; status: set; "Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results FDA reviews of relutrigine, with PDUFA target action date of December 27, 2026, and ulixacaltamide HCI, with PDUFA target action date of January 29, 2027, are ongoing Topline results from the EMERAL"; filed 2026-11-09 · source
Recent milestones
No recent milestones.
Products
No products recorded.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.